Important Steps for Capricor Therapeutics Investors
The Gross Law Firm is reaching out to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR), particularly those who acquired shares during the designated class period. It’s crucial for these investors to take the necessary steps before the September deadline to safeguard their rights.
Understanding the Class Period and Allegations
The class period for this case spans from October 9, 2024, to July 10, 2025. During this time frame, shareholders are encouraged to discuss their experiences with the firm. The legal claims primarily center around the company’s lead cell therapy candidate, deramiocel, aimed at treating cardiomyopathy linked to Duchenne muscular dystrophy (DMD).
Investors were reportedly provided with overly optimistic statements regarding Capricor's efforts to secure a Biologics License Application (BLA) from the U.S. Food and Drug Administration (FDA). However, these statements came alongside misleading information and concealment of adverse facts regarding the safety and efficacy data from the Phase 2 HOPE-2 trial of deramiocel.
On July 11, 2025, Capricor faced significant setbacks when it was announced that the FDA had issued a Complete Response Letter (CRL), denying their BLA due to failure to meet substantial evidence requirements and the need for further clinical data. Following this announcement, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, underscoring the impact of this news on investors.
Deadline for Filing
Investors should not delay registering for this class action as the deadline is approaching on September 15, 2025. Securing a lead plaintiff position is not necessary for participation in the recovery process.
Next Steps for Shareholders
Once registered, shareholders will gain access to a portfolio monitoring tool that will keep them informed about the progress of the case. It’s important that shareholders who purchased shares within the specified date range understand that participation in this case incurs no cost or obligation.
Why Choose Gross Law Firm?
The Gross Law Firm stands out as a reputable class action law firm, dedicated to advocating for investors' rights following cases of deceit and illegal business practices. The firm’s mission includes ensuring companies adhere to ethical business standards while also striving to assist those who have suffered losses due to misleading company statements.
Company Contact Information
For inquiries, investors can contact The Gross Law Firm located at 15 West 38th Street, 12th floor, New York, NY 10018. The team is readily available to provide answers to any questions related to the case and assist investors in navigating their rights.
Frequently Asked Questions
1. What should investors do if they purchased shares during the class period?
Investors should contact The Gross Law Firm to discuss their options and register for the class action.
2. Is there a cost to participate in the class action?
No, joining the class action involves no cost or obligation to shareholders.
3. What is the deadline to register for the class action?
The registration deadline is September 15, 2025.
4. Why is it important to register as a shareholder?
Registering allows investors to stay informed and potentially recover any losses from the events surrounding the case.
5. Can shareholders participate without being a lead plaintiff?
Yes, appointment as a lead plaintiff is not necessary to receive recovery if the class action is successful.
